Furthermore, although predictive biomarkers such as low MHCII levels on circulating CD14+ myeloid cells and tumor PD-L1 status were evaluated in patients treated with eganelisib, patients with and without these biomarkers showed clinical responses. This evidence concerns the gene CD274 and neoplasm.